Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Peer Review reports

Original Submission
28 Aug 2017	Submitted	Original manuscript
29 Sep 2017	Author responded	Author comments - Ehab Atallah
Resubmission - Version 2
29 Sep 2017	Submitted	Manuscript version 2
11 Dec 2017	Author responded	Author comments - Ehab Atallah
Resubmission - Version 3
11 Dec 2017	Submitted	Manuscript version 3
Publishing
20 Mar 2018	Editorially accepted
2 Apr 2018	Article published	10.1186/s12885-018-4273-1

Back to article page